Recent study demonstrates the strong link between SARS-CoV-2 infection and HERV-W activation in hospitalized psychotic patients
Geneva, Switzerland, September 11, 2023 – 7.30 AM CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuro-cognitive consequences of COVID-19 (post-COVID or Long-COVID), today announced, in collaboration with Professor Marion Leboyer from the FondaMental […]